Insmed Incorporated (INSM) Price Target Raised to $211 at BofA

On February 20, BofA expert Jason Zemansky raised the firm’s terms people connected Insmed Incorporated (NASDAQ:INSM) to $211 from $209 and maintained a Buy rating. Although overmuch of the near-term net result had been pre-announced, BofA characterized the consequent net telephone arsenic constructive, highlighting updated Brinsupri guidance for fiscal 2026 of astatine slightest $1 cardinal successful income arsenic a cardinal affirmative development. The guidance supports expanding assurance successful commercialized scale-up and gross durability.

The aforesaid day, Morgan Stanley raised its terms people connected Insmed Incorporated (NASDAQ:INSM) to $166 from $162 and reiterated an Equal Weight rating. While management’s 2026 Brinsupri gross outlook of $1 cardinal oregon much was broadly aligned with expectations, commentary suggesting imaginable enlargement of the U.S. addressable marketplace points to incremental upside beyond archetypal projections.

On February 19, Insmed reported full-year 2025 full revenues of $606.4 million, including BRINSUPRI revenues of $172.7 cardinal for the twelvemonth and $144.6 cardinal successful Q4. ARIKAYCE delivered $119.2 cardinal successful Q4 and $433.8 cardinal for the afloat year, representing 19% yearly maturation and exceeding the precocious extremity of guidance. The operation of accelerating commercialized uptake and expanding marketplace accidental suggests that 2026 could people a pivotal inflection constituent successful gross visibility and operating leverage.

Insmed Incorporated (NASDAQ:INSM) was founded successful 1988. Headquartered successful Bridgewater, New Jersey, Insmed is simply a planetary biopharmaceutical steadfast focused connected processing and commercializing therapies for patients with uncommon and superior diseases, with cardinal assets including brensocatib and Treprostinil Palmitil Inhalation Powder.

While we admit the imaginable of INSM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Best Income Stocks With Highest Upside Potential and 11 Best Low Priced Growth Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey connected Google News.